| Scribe Therapeutics Sets Out to Write CRISPR Gene Editing’s Next Chapter | Frank Vinluan | 10/06/20 | San Francisco |
| Lumen Bioscience Lands $16M to Engineer “Edible” Antibody Drugs | Frank Vinluan | 09/02/20 | Seattle |
| Bio Roundup: Seres Soars, MesoBlast Vote, Duchenne Decision & More | Frank Vinluan | 08/14/20 | National |
| AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact | Frank Vinluan | 08/07/20 | Boston |
| Verve Therapeutics Adds $63M to Edit Heart Attack Risk Out of Genes | Frank Vinluan | 06/11/20 | Boston |
| Regeneron Pays Intellia $100M to Add Hemophilia to CRISPR R&D Pact | Frank Vinluan | 06/01/20 | New York |
| After Inking Bristol Myers Pact, Repare Therapeutics Sets Sights on IPO | Frank Vinluan | 05/29/20 | Boston |
| Viacyte Adds $27M to Move Ahead Trio of Stem Cell Diabetes Treatments | Sarah de Crescenzo | 05/26/20 | San Diego |
| Bio Roundup: Acquisitive Alexion, CRISPR on COVID, C. diff Success & More | Frank Vinluan | 05/08/20 | National |
| Tango Adds $60M in CRISPR Hunt for Synthetically Lethal Cancer Drugs | Frank Vinluan | 04/09/20 | Boston |
| Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More | Sarah de Crescenzo | 03/06/20 | National |
| CRISPR, CAR-T, Consolidation: Top Advanced Therapy Milestones of 2019 | Dan Stanton | 02/12/20 | National |
| FDA Clinical Hold Stops LogicBio’s Gene Editing Study Before It Starts | Frank Vinluan | 02/10/20 | Boston |
| Beam Therapeutics IPO Raises $180M After Nearly Doubling Shares Offered | Sarah de Crescenzo | 02/06/20 | Boston |
| Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More | Frank Vinluan | 01/31/20 | National |
| With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14 | Frank Vinluan | 01/30/20 | San Francisco |
| Emendo Eyes the Clinic for CRISPR Therapy That Makes Single-Gene Edits | Frank Vinluan | 01/22/20 | New York |
| Bio Roundup: EQRx’s Ambitions, Nektar No Vote, New Frazier Fund & More | Frank Vinluan | 01/17/20 | National |
| Emendo Biotherapeutics Nabs $61M for “Next-Generation CRISPR” R&D | Frank Vinluan | 01/15/20 | New York |
| A Safer CRISPR? Cyrus, Broad Institute Look to Quell Concerns | Melissa Fassbender | 12/03/19 | National |
| Bio Roundup: So Long Celgene, RNAi’s Arrival, Pharma in 2020 & More | Frank Vinluan | 11/22/19 | National |
| Bio Roundup: Feds Sue Gilead, Biogen Eyes China, CRISPR’d Kidneys & More | Frank Vinluan | 11/08/19 | National |
| eGenesis Lands $100M to Advance CRISPR-ed Pig Kidney to Human Test | Frank Vinluan | 11/07/19 | Boston |
| Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More | Frank Vinluan | 10/18/19 | National |
| Beam Therapeutics Preps IPO and Sheds Light on Its Gene-Editing Drugs | Frank Vinluan | 09/27/19 | Boston |
| Bio Roundup: Pelosi’s Reveal, Alder’s Deal, Biogen’s Fails & More | Alex Lash | 09/20/19 | National |
| Phil Sharp, CRISPR’ing the Heart & the Duchenne Data Gap on Oct. 17 | Ben Fidler | 09/11/19 | Boston |
| Challenging CRISPR, Trucode Raises $34M for New Gene-Editing System | Frank Vinluan | 09/10/19 | San Francisco |
| Inari Reaps $89M and Eyes Global Farm Markets for Gene-Edited Seeds | Frank Vinluan | 08/06/19 | Boston |
| GlycoMimetics Sickle Cell Drug Flops as Others Creep Forward | Ben Fidler | 08/05/19 | New York |
